JP2012532600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532600A5 JP2012532600A5 JP2012519079A JP2012519079A JP2012532600A5 JP 2012532600 A5 JP2012532600 A5 JP 2012532600A5 JP 2012519079 A JP2012519079 A JP 2012519079A JP 2012519079 A JP2012519079 A JP 2012519079A JP 2012532600 A5 JP2012532600 A5 JP 2012532600A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- amino acids
- isolated
- seq
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001413 amino acids Chemical class 0.000 claims description 149
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 149
- 229920001184 polypeptide Polymers 0.000 claims description 148
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 148
- 230000002163 immunogen Effects 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 101710109637 Antigen 43 Proteins 0.000 description 9
- 101710147195 Hemolysin A Proteins 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108050002207 TonB-dependent siderophore receptors Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 101150084252 gspJ gene Proteins 0.000 description 3
- 101150023725 gspK gene Proteins 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22366409P | 2009-07-07 | 2009-07-07 | |
| US61/223,664 | 2009-07-07 | ||
| US29114009P | 2009-12-30 | 2009-12-30 | |
| US61/291,140 | 2009-12-30 | ||
| PCT/IB2010/001962 WO2011004263A2 (en) | 2009-07-07 | 2010-07-07 | Conserved escherichia coli immunogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012532600A JP2012532600A (ja) | 2012-12-20 |
| JP2012532600A5 true JP2012532600A5 (OSRAM) | 2013-08-15 |
Family
ID=43429616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519079A Withdrawn JP2012532600A (ja) | 2009-07-07 | 2010-07-07 | 保存された大腸菌免疫原 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10988511B2 (OSRAM) |
| EP (1) | EP2451833B1 (OSRAM) |
| JP (1) | JP2012532600A (OSRAM) |
| CN (1) | CN102666571A (OSRAM) |
| AU (1) | AU2010269961A1 (OSRAM) |
| CA (1) | CA2767536A1 (OSRAM) |
| ES (1) | ES2662716T3 (OSRAM) |
| IL (1) | IL217412A0 (OSRAM) |
| MX (1) | MX2012000395A (OSRAM) |
| SG (1) | SG177533A1 (OSRAM) |
| WO (1) | WO2011004263A2 (OSRAM) |
| ZA (1) | ZA201200412B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2755994A2 (en) | 2011-09-14 | 2014-07-23 | Novartis AG | Escherichia coli vaccine combination |
| US20150086592A1 (en) * | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| CL2014001126A1 (es) * | 2014-04-29 | 2014-08-29 | Univ Chile | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
| WO2016011386A1 (en) * | 2014-07-18 | 2016-01-21 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| US10799573B2 (en) * | 2016-03-30 | 2020-10-13 | Regents Of The University Of Minnesota | Pertussis vaccines and methods of making and using |
| RU2019128674A (ru) * | 2017-02-13 | 2021-03-16 | Александр Эдуардо НОВИЛЛ | Иммуногенная композиция для модуляции иммунной системы и способы лечения бактериальных инфекций у субъекта |
| WO2020037376A1 (en) * | 2018-08-23 | 2020-02-27 | La Trobe University | Compositions and methods for reducing bacterial aggregation |
| US12214028B2 (en) | 2019-05-31 | 2025-02-04 | Universidad De Chile | Immunogenic formulation that induces protection against shiga toxin-producing Escherichia coli (STEC) |
| EP3892290A1 (en) * | 2020-04-08 | 2021-10-13 | NUMAFERM GmbH | Variants of hlya and uses thereof |
| WO2021185968A1 (en) * | 2020-03-18 | 2021-09-23 | Numaferm Gmbh | Fragments of hlya and uses thereof |
| CN115466732B (zh) * | 2021-06-10 | 2024-09-03 | 宁夏医科大学 | 用于制备Hispidin的重组蛋白及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| NZ241926A (en) | 1988-08-25 | 1993-08-26 | Liposome Co Inc | Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE69034078T2 (de) | 1989-03-21 | 2004-04-01 | Vical, Inc., San Diego | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| CA2098849C (en) | 1990-12-20 | 2007-07-10 | Ralph R. Weichselbaum | Control of gene expression by ionizing radiation |
| ES2131070T3 (es) | 1991-03-01 | 1999-07-16 | Minnesota Mining & Mfg | 1h-imidazo(4,5-c)quinolin-4-aminas sustituidas en posicion 1 y sustituidas en posicion 2. |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| WO1997042338A1 (en) | 1996-05-06 | 1997-11-13 | Chiron Corporation | Crossless retroviral vectors |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| CA2320223A1 (en) | 1998-02-12 | 1999-08-19 | American Cyanamid Company | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| KR20010042573A (ko) | 1998-04-09 | 2001-05-25 | 장 스테판느 | 애쥬번트 조성물 |
| US6630161B1 (en) | 1998-05-07 | 2003-10-07 | Ribi Immunochem Research, Inc. | Adjuvant composition and methods for its use |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| CN101926993B (zh) | 1998-10-16 | 2013-12-04 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂系统及疫苗 |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| WO2001021207A2 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| TR200200777T2 (tr) | 1999-09-24 | 2002-09-23 | Smithkline Beecham Biologicals S.A. | Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant. |
| PL354997A1 (en) | 1999-09-25 | 2004-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| EP1311288A1 (en) | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
| ATE448226T1 (de) | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
| KR100732206B1 (ko) | 2000-09-11 | 2007-06-27 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 티로신 키나제 억제제로서의 퀴놀리논 유도체 |
| CA2423487C (en) | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| AU2002255798A1 (en) | 2001-04-03 | 2002-10-21 | Biosynexus Incorporated | An animal model for enteric pathogens |
| CA2492826C (en) | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| BR0214407A (pt) | 2001-11-27 | 2004-10-19 | Anadys Pharmaceuticals Inc | Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina |
| DK1499311T3 (da) | 2002-03-29 | 2010-03-08 | Novartis Vaccines & Diagnostic | Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer |
| CA2493690C (en) | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
| EP1537099B1 (en) | 2002-08-23 | 2010-08-11 | Novartis Vaccines and Diagnostics, Inc. | Pyrrole based inhibitors of glycogen synthase kinase 3 |
| AU2003300021A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| ES2391770T3 (es) | 2003-01-21 | 2012-11-29 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos de triptantrina para la potenciación inmune |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
| RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
| US20060089264A1 (en) * | 2004-02-24 | 2006-04-27 | Seungok Hong | Method of heat treating HTc conductors in a large fabricated system |
| BRPI0509606B1 (pt) | 2004-04-05 | 2019-01-15 | Pah Usa 15 Llc | emulsões de óleo-em-água microfluidizadas e composições para vacinas |
| EP1740604A2 (en) * | 2004-04-27 | 2007-01-10 | Intercell AG | Td antigens |
| SI2351772T1 (sl) | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| US8148055B2 (en) * | 2006-06-30 | 2012-04-03 | Infineon Technologies Ag | Method for developing a photoresist |
| JP2010500399A (ja) * | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
| ES2707778T3 (es) * | 2009-12-30 | 2019-04-05 | Glaxosmithkline Biologicals Sa | Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli |
-
2010
- 2010-07-07 US US13/382,906 patent/US10988511B2/en active Active
- 2010-07-07 WO PCT/IB2010/001962 patent/WO2011004263A2/en not_active Ceased
- 2010-07-07 EP EP10749686.1A patent/EP2451833B1/en active Active
- 2010-07-07 MX MX2012000395A patent/MX2012000395A/es not_active Application Discontinuation
- 2010-07-07 ES ES10749686.1T patent/ES2662716T3/es active Active
- 2010-07-07 SG SG2012000931A patent/SG177533A1/en unknown
- 2010-07-07 CA CA2767536A patent/CA2767536A1/en not_active Abandoned
- 2010-07-07 JP JP2012519079A patent/JP2012532600A/ja not_active Withdrawn
- 2010-07-07 AU AU2010269961A patent/AU2010269961A1/en not_active Abandoned
- 2010-07-07 CN CN2010800406195A patent/CN102666571A/zh active Pending
-
2012
- 2012-01-08 IL IL217412A patent/IL217412A0/en unknown
- 2012-01-18 ZA ZA2012/00412A patent/ZA201200412B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532600A5 (OSRAM) | ||
| Ren et al. | Design and evaluation of a multi-epitope assembly peptide vaccine against Acinetobacter baumannii infection in mice | |
| JP2014504851A5 (OSRAM) | ||
| Smit et al. | Structural and functional analysis of the S-layer protein crystallisation domain of Lactobacillus acidophilus ATCC 4356: evidence for protein–protein interaction of two subdomains | |
| Kobierecka et al. | Cell wall anchoring of the Campylobacter antigens to Lactococcus lactis | |
| US12296000B2 (en) | SLAM polynucleotides and polypeptides and uses thereof | |
| Messner et al. | Occurrence, structure, chemistry, genetics, morphogenesis, and functions of S-layers | |
| JP2012532626A5 (OSRAM) | ||
| Nye et al. | Vibrio cholerae H‐NS domain structure and function with respect to transcriptional repression of ToxR regulon genes reveals differences among H‐NS family members | |
| AU739641B2 (en) | Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof | |
| AU2011304942B2 (en) | Fusion protein SAmB, coding gene and application thereof | |
| EP2920203B1 (en) | Recombinant polypeptide construct comprising multiple enterotoxigenic escherichia coli fimbrial subunits | |
| US20050025787A1 (en) | Transformed bacteria producing CS6 antigens as vaccines | |
| Robinson et al. | Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections | |
| CN116514994B (zh) | 一种大肠杆菌多菌毛表位融合蛋白及其制备方法与应用 | |
| Kuebutornye et al. | Molecular cloning and bioinformatics analysis of t3ss inner membrane ring hrpq from Vibrio harveyi | |
| CN103910785B (zh) | 一种荧光假单胞菌TonB依赖型外膜受体及其应用 | |
| Miao et al. | HpaXm from Xanthomonas citri subsp. malvacearum is a novel harpin with two heptads for hypersensitive response | |
| JP6590916B2 (ja) | 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト | |
| KR101830792B1 (ko) | 항균 펩타이드를 포함하는 불용성 융합단백질 및 이를 이용한 항균 펩타이드의 제조 방법 | |
| CN115057945B (zh) | 一种杂合抗菌肽NK-LPd及其基因、载体、制备方法和应用 | |
| Upadhyaya et al. | Molecular cloning and sequence analysis of lamB encoding outer membrane maltose-inducible porin of Aeromonas hydrophila: full length research paper | |
| Cho et al. | An Inducible Expression System for Recombinant Sca Proteins with an Autotransporter Domain from Orientia Tsutsugamushi in Escherichia coli | |
| Zhou et al. | Two groups of S-layer proteins, SLP1s and SLP2s, in Bacillus thuringiensis co-exist in the S-layer and in parasporal inclusions | |
| EP2908852B1 (en) | Lyme disease vaccine |